These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 26470624

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
    Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D, French Society of Dermatology and Club Rheumatisms and Inflammation.
    J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
    [Abstract] [Full Text] [Related]

  • 3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I, Brkić J, Ćorluka M, Čović M, Pejić J, Zeljko Penavić J.
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [Abstract] [Full Text] [Related]

  • 4. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
    Holcomb ZE, Porter ML, Kimball AB.
    Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
    [Abstract] [Full Text] [Related]

  • 5. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC, Maul JT, Yao Y, Wu JJ, Thyssen JP, Thomsen SF, Egeberg A.
    JAMA Dermatol; 2022 Feb 01; 158(2):184-188. PubMed ID: 34851360
    [Abstract] [Full Text] [Related]

  • 6. Biologics for hidradenitis suppurativa: an update.
    Włodarek K, Ponikowska M, Matusiak Ł, Szepietowski JC.
    Immunotherapy; 2019 Jan 01; 11(1):45-59. PubMed ID: 30702012
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2016 Oct 01; 15(10):1192-1196. PubMed ID: 27741335
    [Abstract] [Full Text] [Related]

  • 8. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M, Clark AK, Lee DE, Shi VY.
    J Dermatolog Treat; 2018 Aug 01; 29(5):441-449. PubMed ID: 29098911
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
    Porter ML, Golbari NM, Lockwood SJ, Kimball AB.
    Semin Cutan Med Surg; 2018 Sep 01; 37(3):182-189. PubMed ID: 30215636
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR.
    J Dermatolog Treat; 2012 Aug 01; 23(4):284-9. PubMed ID: 21756155
    [Abstract] [Full Text] [Related]

  • 15. Update on Hidradenitis Suppurative (Part II): Treatment.
    Martorell A, García FJ, Jiménez-Gallo D, Pascual JC, Pereyra-Rodríguez J, Salgado L, Villarrasa E.
    Actas Dermosifiliogr; 2015 Nov 01; 106(9):716-24. PubMed ID: 26277040
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG.
    J Am Acad Dermatol; 2016 May 01; 74(5):851-61.e4. PubMed ID: 26853180
    [Abstract] [Full Text] [Related]

  • 17. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD.
    J Am Acad Dermatol; 2014 Feb 01; 70(2):243-51. PubMed ID: 24314876
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L.
    J Am Acad Dermatol; 2016 Jun 01; 74(6):1066-72. PubMed ID: 27004803
    [Abstract] [Full Text] [Related]

  • 20. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
    Sbidian E, Hotz C, Seneschal J, Maruani A, Amelot F, Aubin F, Paul C, Beylot Barry M, Humbert P, Dupuy A, Caux F, Dupin N, Modiano P, Lepesant P, Ingen-Housz-Oro S, Mahé E, Bachelez H, Chosidow O, Wolkenstein P.
    Br J Dermatol; 2016 Mar 01; 174(3):667-70. PubMed ID: 26406350
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.